P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani,Armando Santoro,Giuseppe Gritti,Pauline Brice,Paul M. Barr,John Kuruvilla,David Cunningham,Justin Kline,Nathalie A. Johnson,Neha Mehta-Shah,Thomas Manley,Stephen Francis,Manish Sharma,Alison J. Moskowitz +13 more
TL;DR: In patients with R/R PMBL, the combination of nivolumab plus BV represents a promising option, with high antitumor activity and a manageable safety profile, according to the Lugano 2014 criteria and safety.
Journal ArticleDOI
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial
Natacha Heutte,Henning Flechtner,Nicolas Mounier,Wilhelmina A. M. Mellink,J.H. Meerwaldt,Houchingue Eghbali,Mars B. van't Veer,Evert M. Noordijk,Johanna Kluin-Nelemans,Elzbieta Lampka,José Thomas,Pieternella J. Lugtenburg,Luisa Viterbo,Patrice Carde,Anton Hagenbeek,Richard W.M. van der Maazen,W.M. Smit,Pauline Brice,Marinus van Marwijk Kooy,Johanna W. Baars,Philip Poortmans,Umberto Tirelli,Onno C. Leeksma,Radka Tomšič,Pierre Feugier,Gilles Salles,Jean Gabarre,Marie José Kersten,Eric Van Den Neste,Geert-Jan Creemers,Isabelle Gaillard,Paul Meijnders,G Tertian,Oumedaly Reman,Hein P. Muller,Jacques Troncy,Michel Blanc,Wilfried Schroyens,Paul J. Voogt,Pierre W. Wijermans,Chantal Rieux,Christophe Fermé,Michel Henry-Amar +42 more
TL;DR: Fatigue status at the end of treatment seems to predict subsequent HRQoL, and patients with Hodgkin's lymphoma show that patients experience strain and limitations in all subdomains apart from cognitive functioning (QLQ-C30), and also have reduced motivation (MFI-20).
Journal ArticleDOI
The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
Robert Kridel,Luc Xerri,Bénédicte Gelas-Dore,King Tan,Pierre Feugier,Ayesha Vawda,Danielle Canioni,Pedro Farinha,Sami Boussetta,Alden A. Moccia,Pauline Brice,Elizabeth A. Chavez,Alastair H. Kyle,David W. Scott,Ashley D. Sanders,Bettina Fabiani,Graham W. Slack,Andrew I. Minchinton,Corinne Haioun,Joseph M. Connors,Laurie H. Sehn,Christian Steidl,Randy D. Gascoyne,Gilles Salles +23 more
TL;DR: CD163-positive macrophages predict outcome in follicular lymphoma, but their prognostic impact is highly dependent on treatment received.
Journal ArticleDOI
Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study
Marleen A. E. van der Kaaij,Natacha Heutte,Paul Meijnders,Edwige Abeilard-Lemoisson,Michele Spina,Elizabeth C. Moser,Anouk Allgeier,Bart Meulemans,Arnold Simons,Pieternella J. Lugtenburg,Berthe M.P. Aleman,Evert M. Noordijk,Christophe Fermé,José Thomas,Aspasia Stamatoullas,Christophe Fruchart,Pauline Brice,Isabelle Gaillard,Serge Bologna,Francisca Ong,Houchingue Eghbali,Jeanette K. Doorduijn,Franck Morschhauser,Catherine Sebban,Judith M. Roesink,Marie Bouteloup,Achiel Van Hoof,John M. M. Raemaekers,Michel Henry-Amar,Hanneke C. Kluin-Nelemans +29 more
TL;DR: Nonalkylating chemotherapy carries little to no excess risk of premature ovarian failure (POF) occurrence and motherhood, and dose-response relationships for alkylating chemotherapy and age at treatment are both linear.
Journal ArticleDOI
Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease : results of the Groupe d'études des Lymphomes de l'Adulte H89 trial
Christophe Fermé,Catherine Sebban,Christophe Hennequin,Marine Divine,Pierre Lederlin,Jean Gabarre,Augustin Ferrant,Denis Caillot,Dominique Bordessoule,Pauline Brice,Isabelle Moullet,Françoise Berger,Eric Lepage +12 more
TL;DR: Results showed that RTx was not superior to CTx consolidation after doxorubicin-induced CR for patients with advanced HD, and 8 cycles of CTx is preferred as standard treatment when a CR has been achieved after 6 cycles.